zavedos
pfizer europe ma eeig - idarubicinas - milteliai injekciniam tirpalui - 5 mg; 10 mg - idarubicin
doxorubicin accord
accord healthcare b.v. - doksorubicino hidrochloridas - koncentratas infuziniam tirpalui - 2 mg/ml - doxorubicin
doxorubicin actavis
actavis group ptc ehf. - doksorubicino hidrochloridas - koncentratas infuziniam tirpalui - 2 mg/ml - doxorubicin
doxorubicin ebewe
sandoz d.d. - doksorubicino hidrochloridas - koncentratas infuziniam tirpalui - 2 mg/ml - doxorubicin
ondansetron kalceks
as kalceks - ondansetronas - injekcinis ar infuzinis tirpalas - 2 mg/ml - ondansetron
cyclophosphamide accord
accord healthcare b.v. - ciklofosfamidas - milteliai injekciniam ar infuziniam tirpalui - 500 mg - cyclophosphamide
cyclophosphamide accord
accord healthcare b.v. - ciklofosfamidas - milteliai injekciniam ar infuziniam tirpalui - 1000 mg - cyclophosphamide
ondansetron kabi
fresenius kabi polska sp.z.o.o. - ondansetronas - infuzinis tirpalas - 0,08 mg/ml - ondansetron
ondansetron kabi
fresenius kabi polska sp.z.o.o. - ondansetronas - infuzinis tirpalas - 0,16 mg/ml - ondansetron
columvi
roche registration gmbh - glofitamab - lymphoma, large b-cell, diffuse - antinavikiniai vaistai - columvi as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl), after two or more lines of systemic therapy.